{"id":53341,"date":"2026-09-14T14:02:28","date_gmt":"2026-09-14T14:02:28","guid":{"rendered":"https:\/\/volity.io\/blog\/scholar-rock-fda-approval-2\/"},"modified":"2026-09-15T07:30:57","modified_gmt":"2026-09-15T07:30:57","slug":"scholar-rock-fda-approval","status":"publish","type":"post","link":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/","title":{"rendered":"L&rsquo;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule"},"content":{"rendered":"<h2>Une approbation dans la biotech se heurte au repli des puces, Wall Street se montre prudent<\/h2>\n\n<p>Wall Street a entam\u00e9 la s\u00e9ance du lundi 14 septembre dans un climat de prudence. Les traders ont all\u00e9g\u00e9 des positions tr\u00e8s encombr\u00e9es sur les semi-conducteurs tout en guettant de nouveaux catalyseurs d&rsquo;entreprise.<\/p>\n\n<p>Les semi-conducteurs ont donn\u00e9 le ton d\u00e9fensif d\u00e8s le d\u00e9but. La biotech offrait toutefois une opportunit\u00e9 d&rsquo;une tout autre nature.<\/p>\n\n<p>Scholar Rock s&rsquo;est impos\u00e9e comme la valeur \u00e9v\u00e9nementielle la plus nette de la matin\u00e9e. La FDA a approuv\u00e9 ISEMBYLD pour les patients atteints d&rsquo;amyotrophie spinale \u00e2g\u00e9s de deux ans et plus.<\/p>\n\n<p>Le traitement cible les patients qui re\u00e7oivent d\u00e9j\u00e0 des th\u00e9rapies dirig\u00e9es vers SMN2, notamment le nusinersen ou le risdiplam. L&rsquo;approbation donne donc \u00e0 Scholar Rock son premier produit commercialis\u00e9.<\/p>\n\n<p>La direction a programm\u00e9 une conf\u00e9rence t\u00e9l\u00e9phonique consacr\u00e9e \u00e0 l&rsquo;approbation \u00e0 8 h, heure de l&rsquo;Est. Les investisseurs attendaient des pr\u00e9cisions sur l&rsquo;\u00e9tiquetage, le calendrier de lancement, le remboursement et l&rsquo;infrastructure commerciale.<\/p>\n\n<p>ISEMBYLD s&rsquo;accompagne aussi d&rsquo;un bon d&rsquo;examen prioritaire. Cet actif pourrait avoir une valeur significative, soit par une cession, soit pour le d\u00e9veloppement de futurs m\u00e9dicaments.<\/p>\n\n<p>Truist a relev\u00e9 son objectif de cours sur Scholar Rock apr\u00e8s la d\u00e9cision. La soci\u00e9t\u00e9 a mis en avant une trajectoire de croissance plus longue sur le march\u00e9 de la SMA.<\/p>\n\n<p>SRRK entre toutefois dans une phase plus exigeante. Le risque li\u00e9 \u00e0 l&rsquo;approbation est pass\u00e9, mais le risque d&rsquo;ex\u00e9cution commerciale est arriv\u00e9.<\/p>\n\n<p>Les traders chercheront \u00e0 savoir si la direction chiffre la demande initiale. Ils attendront aussi des indications sur la prospection aupr\u00e8s des sp\u00e9cialistes et la couverture par les assureurs.<\/p>\n\n<h3>Intel rend du terrain<\/h3>\n\n<p>L&rsquo;action Intel a recul\u00e9 de plus de 6 % en d\u00e9but de s\u00e9ance. Ce mouvement a prolong\u00e9 un r\u00e9cent repli du secteur des semi-conducteurs.<\/p>\n\n<p>Cette faiblesse fait suite \u00e0 une envol\u00e9e exceptionnelle. INTC avait gagn\u00e9 environ 188 % depuis le d\u00e9but de l&rsquo;ann\u00e9e avant les ventes de lundi.<\/p>\n\n<p>De tels gains laissent peu de place \u00e0 la d\u00e9ception. Les inqui\u00e9tudes sur la demande de puces et sur les marges ont donc pes\u00e9 davantage.<\/p>\n\n<p>Les r\u00e9cents commentaires des analystes c\u00f4t\u00e9 vendeur ont aussi refroidi le sentiment. Les analystes ont remis en question la trajectoire des b\u00e9n\u00e9fices d&rsquo;Intel \u00e0 court terme et la visibilit\u00e9 de la demande.<\/p>\n\n<p>Le titre est devenu tr\u00e8s sensible aux rendements et aux flux sectoriels. Les \u00e9l\u00e9ments propres \u00e0 l&rsquo;entreprise sont d\u00e9sormais en concurrence avec l&rsquo;app\u00e9tit g\u00e9n\u00e9ral pour le risque.<\/p>\n\n<p>L&rsquo;iShares Semiconductor ETF est rest\u00e9 sous ses sommets de fin d&rsquo;\u00e9t\u00e9. Dans le m\u00eame temps, les valeurs des puces ont r\u00e9cemment chut\u00e9 plus vite que l&rsquo;ensemble du secteur technologique.<\/p>\n\n<p>Cette distinction compte pour les traders. Intel se comporte moins comme une histoire de redressement que comme une position encombr\u00e9e et sensible aux taux.<\/p>\n\n<ul>\n  <li><b>INTC :<\/b> En baisse de plus de 6 % lundi en d\u00e9but de s\u00e9ance, apr\u00e8s une hausse d&rsquo;environ 188 % depuis le d\u00e9but de l&rsquo;ann\u00e9e.<\/li>\n  <li><b>SRRK :<\/b> L&rsquo;approbation de la FDA, le lancement du produit et la conf\u00e9rence de la direction cr\u00e9ent un catalyseur actif.<\/li>\n  <li><b>CHTR :<\/b> Les baisses d&rsquo;objectifs de cours renforcent les inqui\u00e9tudes sur la croissance du haut d\u00e9bit et la concurrence.<\/li>\n  <li><b>SPY et QQQ :<\/b> Restent des instruments cl\u00e9s pour exprimer la prudence avant la r\u00e9union de la R\u00e9serve f\u00e9d\u00e9rale (Fed).<\/li>\n<\/ul>\n\n<h3>Le logiciel trouve un appui plus solide<\/h3>\n\n<p>La hausse des rendements du Tr\u00e9sor am\u00e9ricain a favoris\u00e9 une rotation vers les valeurs per\u00e7ues comme de qualit\u00e9. Les investisseurs n&rsquo;ont toutefois pas totalement d\u00e9laiss\u00e9 la technologie.<\/p>\n\n<p>Les grandes plateformes logicielles ont mieux r\u00e9sist\u00e9 que les valeurs sp\u00e9culatives du mat\u00e9riel. ServiceNow a profit\u00e9 de cette force relative.<\/p>\n\n<p>Les valeurs de cybers\u00e9curit\u00e9 ont aussi attir\u00e9 l&rsquo;int\u00e9r\u00eat des investisseurs institutionnels. CrowdStrike et Palo Alto Networks r\u00e9pondent \u00e0 une pr\u00e9f\u00e9rence pour les revenus r\u00e9currents et une demande visible.<\/p>\n\n<p>Les investisseurs consid\u00e8rent de plus en plus ces groupes comme des couvertures d\u00e9fensives face \u00e0 l&rsquo;IA. \u00c0 l&rsquo;inverse, les valeurs du mat\u00e9riel sont plus sensibles aux valorisations et aux cha\u00eenes d&rsquo;approvisionnement.<\/p>\n\n<p>Il ne s&rsquo;agit pas d&rsquo;une fuite g\u00e9n\u00e9ralis\u00e9e hors des valeurs de croissance. C&rsquo;est plut\u00f4t un mouvement vers des entreprises aux flux de tr\u00e9sorerie \u00e9tablis et aux revenus d&rsquo;abonnement.<\/p>\n\n<p>Oracle, Nvidia et Micron restent d&rsquo;importants barom\u00e8tres du march\u00e9. Chacune \u00e9volue pourtant d\u00e9sormais dans un contexte moins cl\u00e9ment pour les actifs \u00e0 longue duration.<\/p>\n\n<p>Tesla reste aussi un indicateur utile de l&rsquo;app\u00e9tit sp\u00e9culatif. L&rsquo;activit\u00e9 sur les options sugg\u00e8re que le positionnement \u00e0 court terme guide encore une grande partie de ses \u00e9changes.<\/p>\n\n<h3>Charter reste sous pression<\/h3>\n\n<p>Charter Communications est rest\u00e9e dans le viseur des traders apr\u00e8s une nouvelle s\u00e9rie de commentaires prudents des analystes. Le c\u00e2blo-op\u00e9rateur fait face \u00e0 des attentes qui se d\u00e9gradent sur la croissance du haut d\u00e9bit.<\/p>\n\n<p>Bernstein SocGen a abaiss\u00e9 son objectif sur Charter \u00e0 $150, contre $170 auparavant, au cours de l&rsquo;\u00e9t\u00e9. Le courtier a maintenu une recommandation market-perform.<\/p>\n\n<p>La soci\u00e9t\u00e9 a invoqu\u00e9 la concurrence et des perspectives plus difficiles pour le haut d\u00e9bit. Depuis, des notes plus r\u00e9centes \u00e9voquent un potentiel de baisse vers le bas de la fourchette des $100.<\/p>\n\n<p>Ces objectifs ne repr\u00e9sentent pas le consensus. Leur orientation refl\u00e8te n\u00e9anmoins une remise \u00e0 plat plus large des attentes dans le secteur du c\u00e2ble.<\/p>\n\n<p>Les investisseurs voyaient autrefois Charter comme une valeur de croissance s\u00e9culaire et durable. Le march\u00e9 la consid\u00e8re d\u00e9sormais de plus en plus comme un op\u00e9rateur \u00e0 croissance plus lente, soumis \u00e0 une forte pression concurrentielle.<\/p>\n\n<p>Ce changement peut \u00eatre difficile \u00e0 inverser. Toute reprise n\u00e9cessitera donc probablement des donn\u00e9es d&rsquo;abonn\u00e9s en voie de stabilisation plut\u00f4t que de simples multiples de valorisation plus bas.<\/p>\n\n<h3>Les valeurs d\u00e9cot\u00e9es attendent des signaux plus clairs<\/h3>\n\n<p>Ailleurs, les strat\u00e9gies de rendement et de valeur ont continu\u00e9 de mijoter sous les gros titres technologiques. Thor Industries illustre cette tension.<\/p>\n\n<p>Son rendement peut s\u00e9duire les investisseurs en qu\u00eate de revenus. Des attentes de b\u00e9n\u00e9fices plus faibles maintiennent toutefois le titre li\u00e9 au cycle industriel.<\/p>\n\n<p>Freeport-McMoRan, Delta Air Lines et Kimberly-Clark restent aussi sur les listes de surveillance actives. Chacune d\u00e9pend de variables macro\u00e9conomiques diff\u00e9rentes.<\/p>\n\n<p>Freeport a besoin du soutien de la demande de cuivre. Delta a besoin de d\u00e9penses de voyage r\u00e9sistantes, tandis que Kimberly-Clark a besoin d&rsquo;une demande de consommation et de co\u00fbts d&rsquo;intrants plus stables.<\/p>\n\n<p>Pour l&rsquo;instant, peu d&rsquo;investisseurs semblent press\u00e9s de prendre des engagements d\u00e9mesur\u00e9s. La r\u00e9union de la R\u00e9serve f\u00e9d\u00e9rale et les prix de l&rsquo;\u00e9nergie pourraient changer ce calcul.<\/p>\n\n<h3>Ce que surveillent les traders<\/h3>\n\n<ol>\n  <li>Les projets de lancement de Scholar Rock, les commentaires sur le remboursement et tout premier indicateur de la demande pour ISEMBYLD.<\/li>\n  <li>La capacit\u00e9 d&rsquo;Intel \u00e0 tenir apr\u00e8s son net recul par rapport aux sommets de cette ann\u00e9e.<\/li>\n  <li>De nouvelles baisses d&rsquo;objectifs ou des avertissements sur les abonn\u00e9s touchant Charter.<\/li>\n  <li>Les rendements du Tr\u00e9sor am\u00e9ricain, qui continuent d&rsquo;orienter les valeurs de croissance ch\u00e8res.<\/li>\n  <li>Les anticipations sur la Fed, exprim\u00e9es rapidement via SPY, QQQ et les principales options technologiques.<\/li>\n<\/ol>\n\n<p>La s\u00e9ance de lundi a offert une ligne de partage simple. Les catalyseurs r\u00e9els et dat\u00e9s ont concentr\u00e9 l&rsquo;attention.<\/p>\n\n<p>Scholar Rock avait une approbation et une conf\u00e9rence. Intel a connu des prises de b\u00e9n\u00e9fices visibles, tandis que Charter subissait une nouvelle pression li\u00e9e aux d\u00e9gradations.<\/p>\n\n<p>\u00c0 l&rsquo;inverse, les r\u00e9cits de long terme autour de l&rsquo;IA semblaient moins exploitables. Les traders se sont davantage int\u00e9ress\u00e9s \u00e0 ce qui pourrait modifier les estimations cette semaine.<\/p>\n\n<p>Sur ce march\u00e9, le timing compte autant que la conviction. Un catalyseur valid\u00e9 peut faire bouger rapidement un cours, tandis qu&rsquo;un th\u00e8me populaire peut s&rsquo;essouffler tout aussi vite.<\/p>\n\n\n<h2 class=\"wp-block-heading volity-related-coverage\">Articles connexes sur Volity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/what-is-a-pe-ratio\/\">Qu&rsquo;est-ce qu&rsquo;un PER et comment l&rsquo;utiliser<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/fundamental-analysis-stock-trading\/\">Analyse fondamentale en trading d&rsquo;actions : une d\u00e9finition op\u00e9rationnelle<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/growth-investing-vs-value-investing\/\">Investissement growth vs investissement value : quel style vous convient ?<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/fractional-shares-explained\/\">Actions fractionn\u00e9es expliqu\u00e9es : comment commencer \u00e0 investir avec $50<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/how-to-start-stock-trading\/\">Comment commencer le trading d&rsquo;actions : un guide d\u00e9butant 2026<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/fr\/actions\/dividend-investing-for-beginners\/\">Investissement de dividendes pour d\u00e9butants : comment commencer<\/a><\/li>\n<\/ul>\n\n\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-14T14:02:28+00:00\",\"author\":{\"@type\":\"Person\",\"name\":\"Alexander Bennett\",\"url\":\"https:\/\/volity.io\/\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Volity\",\"url\":\"https:\/\/volity.io\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/logo.webp\",\"width\":512,\"height\":512}},\"image\":\"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/\"},\"articleSection\":\"News\",\"inLanguage\":\"fr\"}<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Une approbation dans la biotech se heurte au repli des puces, Wall Street se montre prudent Wall Street a entam\u00e9 la s\u00e9ance [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":53335,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"custom_schema":"","footnotes":""},"categories":[223],"tags":[],"class_list":["post-53341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>L&#039;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule | Volity<\/title>\n<meta name=\"description\" content=\"La FDA a approuv\u00e9 l&#039;ISEMBYLD de Scholar Rock contre l&#039;amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu&#039;Intel recule et que Wall Street se\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule\" \/>\n<meta property=\"og:description\" content=\"La FDA a approuv\u00e9 l&#039;ISEMBYLD de Scholar Rock contre l&#039;amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu&#039;Intel recule et que Wall Street se\" \/>\n<meta property=\"og:url\" content=\"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"Volity\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61570055360264\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T14:02:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-15T07:30:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"669\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Alexander Bennett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:site\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexander Bennett\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/\"},\"author\":{\"name\":\"Alexander Bennett\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\"},\"headline\":\"L&rsquo;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-15T07:30:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/\"},\"wordCount\":1472,\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"articleSection\":[\"News\"],\"inLanguage\":\"fr-FR\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/\",\"name\":\"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule | Volity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-15T07:30:57+00:00\",\"description\":\"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se montre prudente.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/\"]}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"width\":1200,\"height\":669,\"caption\":\"Scholar Rock FDA Approval Sends SRRK Into Focus as Intel Falls\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/actualites\\\/scholar-rock-fda-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/volity.io\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&#8217;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/volity.io\\\/fr\\\/\",\"name\":\"Volity - Effortless, Affordable & Transparent Access To Financial Markets\",\"description\":\"O\u00f9 chaque volume trouve son agilit\u00e9\",\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#organization\"},\"alternateName\":\"Volity Empowers Financial Inclusion\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/volity.io\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#organization\",\"name\":\"Volity\",\"alternateName\":[\"VLT\",\"Volity Group\"],\"url\":\"https:\\\/\\\/volity.io\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"width\":1920,\"height\":1357,\"caption\":\"VOLITY\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61570055360264\",\"https:\\\/\\\/x.com\\\/VolityBeat\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/volitygroup\",\"https:\\\/\\\/www.youtube.com\\\/@VolityYoutube\",\"https:\\\/\\\/www.tiktok.com\\\/@hellovolity\",\"https:\\\/\\\/t.me\\\/volitybeat\",\"https:\\\/\\\/www.trustpilot.com\\\/review\\\/volity.io\"],\"foundingDate\":\"2024\",\"legalName\":\"Volity Capital L.L.C-FZ\",\"address\":{\"@type\":\"PostalAddress\",\"addressCountry\":\"CY\",\"addressLocality\":\"Limassol\",\"streetAddress\":\"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor\",\"postalCode\":\"4003\"},\"contactPoint\":[{\"@type\":\"ContactPoint\",\"contactType\":\"customer support\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"availableLanguage\":[\"English\",\"German\",\"French\",\"Spanish\"],\"areaServed\":[\"EU\",\"GB\",\"Worldwide\"]}],\"knowsAbout\":[\"Forex trading\",\"Contract for difference (CFD) trading\",\"Cryptocurrency trading\",\"Gold and commodities trading\",\"Stock trading\",\"Indices trading\",\"Multi-asset investment platforms\",\"Risk management\"],\"subOrganization\":[{\"@type\":\"Organization\",\"name\":\"Volity Trade Ltd\",\"identifier\":\"Saint Lucia 2024-00059\",\"description\":\"Introducing broker for UBK Markets Ltd\"},{\"@type\":\"Organization\",\"name\":\"Volity Invest Ltd\",\"identifier\":\"Cyprus HE 452984\",\"description\":\"Payment agent\"},{\"@type\":\"Organization\",\"name\":\"Volity Capital L.L.C-FZ\",\"identifier\":\"Dubai trademark 2423068\"}],\"description\":\"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"memberOf\":{\"@type\":\"Organization\",\"name\":\"CySEC, Cyprus Securities and Exchange Commission\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\",\"description\":\"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\\\/12.\"},\"hasCredential\":{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"CySEC CIF licence (via UBK Markets Ltd)\",\"credentialCategory\":\"Regulatory authorisation\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"CySEC\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\"},\"identifier\":\"186\\\/12\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\",\"name\":\"Alexander Bennett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"caption\":\"Alexander Bennett\"},\"description\":\"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/alexanderbennettfm\\\/\",\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\"],\"jobTitle\":\"Financial Analyst & Trading Strategy Expert\",\"givenName\":\"Alexander\",\"familyName\":\"Bennett\",\"url\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"worksFor\":{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/#organization\",\"name\":\"Volity\"},\"knowsAbout\":[\"Forex trading\",\"Cryptocurrency markets\",\"Technical analysis\",\"Risk management\",\"CFD trading\",\"Commodities trading\",\"Trading strategy\",\"TradingView charting\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule | Volity","description":"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/","og_locale":"fr_FR","og_type":"article","og_title":"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule","og_description":"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se","og_url":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/","og_site_name":"Volity","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61570055360264","article_published_time":"2026-09-14T14:02:28+00:00","article_modified_time":"2026-09-15T07:30:57+00:00","og_image":[{"width":1200,"height":669,"url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","type":"image\/webp"}],"author":"Alexander Bennett","twitter_card":"summary_large_image","twitter_creator":"@VolityBeat","twitter_site":"@VolityBeat","twitter_misc":{"\u00c9crit par":"Alexander Bennett","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#article","isPartOf":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/"},"author":{"name":"Alexander Bennett","@id":"https:\/\/volity.io\/alexander-bennett\/#person"},"headline":"L&rsquo;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule","datePublished":"2026-09-14T14:02:28+00:00","dateModified":"2026-09-15T07:30:57+00:00","mainEntityOfPage":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/"},"wordCount":1472,"publisher":{"@id":"https:\/\/volity.io\/fr\/#organization"},"image":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","articleSection":["News"],"inLanguage":"fr-FR","speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"WebPage","@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/","url":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/","name":"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule | Volity","isPartOf":{"@id":"https:\/\/volity.io\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#primaryimage"},"image":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","datePublished":"2026-09-14T14:02:28+00:00","dateModified":"2026-09-15T07:30:57+00:00","description":"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se montre prudente.","breadcrumb":{"@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/"]}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#primaryimage","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","width":1200,"height":669,"caption":"Scholar Rock FDA Approval Sends SRRK Into Focus as Intel Falls"},{"@type":"BreadcrumbList","@id":"https:\/\/volity.io\/fr\/actualites\/scholar-rock-fda-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/volity.io\/fr\/"},{"@type":"ListItem","position":2,"name":"L&#8217;approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule"}]},{"@type":"WebSite","@id":"https:\/\/volity.io\/fr\/#website","url":"https:\/\/volity.io\/fr\/","name":"Volity - Effortless, Affordable & Transparent Access To Financial Markets","description":"O\u00f9 chaque volume trouve son agilit\u00e9","publisher":{"@id":"https:\/\/volity.io\/fr\/#organization"},"alternateName":"Volity Empowers Financial Inclusion","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/volity.io\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/volity.io\/fr\/#organization","name":"Volity","alternateName":["VLT","Volity Group"],"url":"https:\/\/volity.io\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/volity.io\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","width":1920,"height":1357,"caption":"VOLITY"},"image":{"@id":"https:\/\/volity.io\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61570055360264","https:\/\/x.com\/VolityBeat","https:\/\/www.linkedin.com\/company\/volitygroup","https:\/\/www.youtube.com\/@VolityYoutube","https:\/\/www.tiktok.com\/@hellovolity","https:\/\/t.me\/volitybeat","https:\/\/www.trustpilot.com\/review\/volity.io"],"foundingDate":"2024","legalName":"Volity Capital L.L.C-FZ","address":{"@type":"PostalAddress","addressCountry":"CY","addressLocality":"Limassol","streetAddress":"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor","postalCode":"4003"},"contactPoint":[{"@type":"ContactPoint","contactType":"customer support","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","availableLanguage":["English","German","French","Spanish"],"areaServed":["EU","GB","Worldwide"]}],"knowsAbout":["Forex trading","Contract for difference (CFD) trading","Cryptocurrency trading","Gold and commodities trading","Stock trading","Indices trading","Multi-asset investment platforms","Risk management"],"subOrganization":[{"@type":"Organization","name":"Volity Trade Ltd","identifier":"Saint Lucia 2024-00059","description":"Introducing broker for UBK Markets Ltd"},{"@type":"Organization","name":"Volity Invest Ltd","identifier":"Cyprus HE 452984","description":"Payment agent"},{"@type":"Organization","name":"Volity Capital L.L.C-FZ","identifier":"Dubai trademark 2423068"}],"description":"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","memberOf":{"@type":"Organization","name":"CySEC, Cyprus Securities and Exchange Commission","url":"https:\/\/www.cysec.gov.cy\/","description":"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\/12."},"hasCredential":{"@type":"EducationalOccupationalCredential","name":"CySEC CIF licence (via UBK Markets Ltd)","credentialCategory":"Regulatory authorisation","recognizedBy":{"@type":"Organization","name":"CySEC","url":"https:\/\/www.cysec.gov.cy\/"},"identifier":"186\/12"}},{"@type":"Person","@id":"https:\/\/volity.io\/alexander-bennett\/#person","name":"Alexander Bennett","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","caption":"Alexander Bennett"},"description":"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\/\/volity.io\/alexander-bennett\/","sameAs":["https:\/\/www.linkedin.com\/in\/alexanderbennettfm\/","https:\/\/volity.io\/alexander-bennett\/"],"jobTitle":"Financial Analyst & Trading Strategy Expert","givenName":"Alexander","familyName":"Bennett","url":"https:\/\/volity.io\/alexander-bennett\/","worksFor":{"@type":"Organization","@id":"https:\/\/volity.io\/#organization","name":"Volity"},"knowsAbout":["Forex trading","Cryptocurrency markets","Technical analysis","Risk management","CFD trading","Commodities trading","Trading strategy","TradingView charting"]}]}},"yoast_meta":{"yoast_wpseo_title":"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule %%sep%% %%sitename%%","yoast_wpseo_metadesc":"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se montre prudente.","yoast_wpseo_focuskw":"scholar rock approbation fda srrk","yoast_wpseo_opengraph-title":"","yoast_wpseo_opengraph-description":"","yoast_wpseo_twitter-title":"","yoast_wpseo_twitter-description":""},"yoast_title":"L'approbation de la FDA place Scholar Rock (SRRK) sous les projecteurs, Intel recule %%sep%% %%sitename%%","yoast_metadesc":"La FDA a approuv\u00e9 l'ISEMBYLD de Scholar Rock contre l'amyotrophie spinale, pla\u00e7ant SRRK sous les projecteurs alors qu'Intel recule et que Wall Street se montre prudente.","_links":{"self":[{"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/posts\/53341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/comments?post=53341"}],"version-history":[{"count":0,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/posts\/53341\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/media\/53335"}],"wp:attachment":[{"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/media?parent=53341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/categories?post=53341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/volity.io\/fr\/wp-json\/wp\/v2\/tags?post=53341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}